Form 4: Tyra Biosciences COO Daniel Bensen Sells 200 Shares of Common Stock

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, sold 200 shares of common stock on March 11, 2024, at a price of $20 per share.

Summary

• On March 11, 2024, Daniel Bensen, the Chief Operating Officer of Tyra Biosciences, sold 200 shares of the company's common stock.
• The sale was executed at a price of $20 per share.
• Following the transaction, Bensen directly owns 431,683 shares of Tyra Biosciences common stock.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 7, 2022.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale by an insider under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like the COO in this case, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any recent non-public information.

Stakeholder Impact

• The sale of shares by a company insider could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates